This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Stadler, Z.K., et al., Genome-wide association studies of cancer. J Clin Oncol, 2010. 28(27): p. 4255-67.StadlerZ.K.et al.Genome-wide association studies of cancer2010282742556710.1200/JCO.2009.25.7816295397620585100Search in Google Scholar
Foulkes, W.D., Inherited susceptibility to common cancers. N Engl J Med, 2008. 359(20): p. 2143-53.FoulkesW.D.Inherited susceptibility to common cancers20083592021435310.1056/NEJMra080296819005198Search in Google Scholar
Ford, D., et al., Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet, 1998. 62(3): p. 676-89.FordD.et al.Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium19986236768910.1086/30174913769449497246Search in Google Scholar
Yurgelun, M.B., E. Hiller, and J.E. Garber, Population-Wide Screening for Germline BRCA1 and BRCA2 Mutations: Too Much of a Good Thing? J Clin Oncol, 2015.YurgelunM.B.HillerE.GarberJ.E.Population-Wide Screening for Germline BRCA1 and BRCA2 Mutations: Too Much of a Good Thing?201510.1200/JCO.2015.60.859626282646Search in Google Scholar
Tsigginou, A., et al., Cumulative BRCA mutation analysis in the Greek population confirms that homogenous ethnic background facilitates genetic testing. Hered Cancer Clin Pract, 2015. 13(1): p. 17.TsigginouA.et al.Cumulative BRCA mutation analysis in the Greek population confirms that homogenous ethnic background facilitates genetic testing20151311710.1186/s13053-015-0037-y454532926300996Search in Google Scholar
Fostira, F., et al., Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. Breast Cancer Res Treat, 2012. 134(1): p. 353-62.FostiraF.et al.Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study201213413536210.1007/s10549-012-2021-922434525Search in Google Scholar
Stavropoulou, A.V., et al., Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases. PLoS One, 2013. 8(3): p. e58182.StavropoulouA.V.et al.Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases201383e5818210.1371/journal.pone.0058182359424123536787Search in Google Scholar
Petrucelli, N., M.B. Daly, and G.L. Feldman, BRCA1 and BRCA2 Hereditary Breast and Ovarian Cancer, in GeneReviews(R), R.A. Pagon, et al., Editors. 1993: Seattle (WA).PetrucelliN.DalyM.B.FeldmanG.L.BRCA1 and BRCA2 Hereditary Breast and Ovarian CancerPagonR.A.et al.1993Seattle (WA)Search in Google Scholar
Litton, J.K., et al., Earlier age of onset of BRCA mutation-related cancers in subsequent generations. Cancer, 2012. 118(2): p. 321-5.LittonJ.K.et al.Earlier age of onset of BRCA mutation-related cancers in subsequent generations20121182321510.1002/cncr.26284436937721913181Search in Google Scholar
Martinez-Delgado, B., et al., Genetic anticipation is associated with telomere shortening in hereditary breast cancer. PLoS Genet, 2011. 7(7): p. e1002182.Martinez-DelgadoB.et al.Genetic anticipation is associated with telomere shortening in hereditary breast cancer201177e100218210.1371/journal.pgen.1002182314562121829373Search in Google Scholar
Lubinski, J., et al., Cancer variation associated with the position of the mutation in the BRCA2 gene. Fam Cancer, 2004. 3(1): p. 1-10.LubinskiJ.et al.Cancer variation associated with the position of the mutation in the BRCA2 gene20043111010.1023/B:FAME.0000026816.32400.45Search in Google Scholar
Masciari, S., et al., Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Res Treat, 2012. 133(3): p. 1125-30.MasciariS.et al.Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort2012133311253010.1007/s10549-012-1993-9Search in Google Scholar
Riley, B.D., et al., Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns, 2012. 21(2): p. 151-61.RileyB.D.et al.Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors20122121516110.1007/s10897-011-9462-xSearch in Google Scholar
Robson, M.E., et al., American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. J Clin Oncol, 2015.RobsonM.E.et al.American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility201510.1200/JCO.2015.63.0996Search in Google Scholar
Kurian, A.W., et al., Performance of prediction models for BRCA mutation carriage in three racial/ ethnic groups: findings from the Northern California Breast Cancer Family Registry. Cancer Epidemiol Biomarkers Prev, 2009. 18(4): p. 1084-91.KurianA.W.et al.Performance of prediction models for BRCA mutation carriage in three racial/ ethnic groups: findings from the Northern California Breast Cancer Family Registry200918410849110.1158/1055-9965.EPI-08-1090Search in Google Scholar
NCCN, www.nccn.org(last accessed on 20 Jul 2015).NCCNwww.nccn.orglast accessed on20 Jul 2015Search in Google Scholar
Daly, M.B., et al., Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw, 2010. 8(5): p. 562-94.DalyM.B.et al.Genetic/familial high-risk assessment: breast and ovarian2010855629410.6004/jnccn.2010.0043Search in Google Scholar
Saslow, D., et al., American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin, 2007. 57(2): p. 75-89.SaslowD.et al.American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography2007572758910.3322/canjclin.57.2.75Search in Google Scholar
Scheuer, L., et al., Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol, 2002. 20(5): p. 1260-8.ScheuerL.et al.Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers20022051260810.1200/JCO.2002.20.5.1260Search in Google Scholar
Bick, U., Intensified surveillance for early detection of breast cancer in high-risk patients. Breast Care (Basel), 2015. 10(1): p. 13-20.BickU.Intensified surveillance for early detection of breast cancer in high-risk patients2015101132010.1159/000375390Search in Google Scholar
Chiarelli, A.M., et al., Effectiveness of screening with annual magnetic resonance imaging and mammography: results of the initial screen from the ontario high risk breast screening program. J Clin Oncol, 2014. 32(21): p. 2224-30.ChiarelliA.M.et al.Effectiveness of screening with annual magnetic resonance imaging and mammography: results of the initial screen from the ontario high risk breast screening program2014322122243010.1200/JCO.2013.52.8331Search in Google Scholar
Narod, S.A., et al., Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet Oncol, 2006. 7(5): p. 402-6.NarodS.A.et al.Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study200675402610.1016/S1470-2045(06)70624-6Search in Google Scholar
Kauff, N.D., et al., Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med, 2002. 346(21): p. 1609-15.KauffN.D.et al.Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation20023462116091510.1097/00006254-200209000-00016Search in Google Scholar
Rebbeck, T.R., et al., Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med, 2002. 346(21): p. 1616-22.RebbeckT.R.et al.Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations20023462116162210.1016/S0959-8049(02)00269-1Search in Google Scholar
Finch, A.P., et al., Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol, 2014. 32(15): p. 1547-53.FinchA.P.et al.Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation2014321515475310.1200/JCO.2013.53.2820Search in Google Scholar
Narod, S.A., et al., Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet, 2000. 356(9245): p. 1876-81.NarodS.A.et al.Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group2000356924518768110.1016/S0140-6736(00)03258-XSearch in Google Scholar
King, M.C., et al., Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA, 2001. 286(18): p. 2251-6.KingM.C.et al.Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial2001286182251610.1001/jama.286.18.225111710890Search in Google Scholar
Cibula, D., et al., Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Rev Anticancer Ther, 2011. 11(8): p. 1197-207.CibulaD.et al.Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis2011118119720710.1586/era.11.3821916573Search in Google Scholar
Iodice, S., et al., Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a metaanalysis. Eur J Cancer, 2010. 46(12): p. 2275-84.IodiceS.et al.Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a metaanalysis2010461222758410.1016/j.ejca.2010.04.01820537530Search in Google Scholar
Tutt A, et al: The TNT trial. 2014 San Antonio Breast Cancer Symposium. Abstract S3-01. Presented December 11, 2014.TuttAet alThe TNT trialAbstractS301PresentedDecember 11, 2014Search in Google Scholar
Walsh, C.S., Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy. Gynecol Oncol, 2015. 137(2): p. 343-50.WalshC.S.Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy201513723435010.1016/j.ygyno.2015.02.01725725131Search in Google Scholar
Kurian, A.W. and J.M. Ford, Multigene Panel Testing in Oncology Practice: How Should We Respond? JAMA Oncol, 2015. 1(3): p. 277-8.KurianA.W.FordJ.M.Multigene Panel Testing in Oncology Practice: How Should We Respond?201513277810.1001/jamaoncol.2015.2826181167Search in Google Scholar
Desmond, A., et al., Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. JAMA Oncol, 2015. 1(7): p. 943-51.DesmondA.et al.Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment2015179435110.1001/jamaoncol.2015.269026270727Search in Google Scholar
Gaudet, M.M., et al., Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genet, 2013. 9(3): p. e1003173.GaudetM.M.et al.Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk201393e100317310.1371/journal.pgen.1003173360964723544012Search in Google Scholar
Couch, F.J., et al., Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet, 2013. 9(3): p. e1003212.CouchF.J.et al.Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk201393e100321210.1371/journal.pgen.1003212360964623544013Search in Google Scholar
King, M.C., E. Levy-Lahad, and A. Lahad, Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award. JAMA, 2014. 312(11): p. 1091-2.KingM.C. Levy-LahadE.LahadA.Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award2014312111091210.1001/jama.2014.1248325198398Search in Google Scholar
Georgios Lypas, K.P., Georgia Georgiou, Menelaos Zoulamoglou, Nikolaos Tsoukalas, Georgios Zografos, Pavlos Papakostas, Vasileios Barbounis, Identification of breast cancer patients fulfilling NCCN criteria for genetic risk assessment. J Clin Oncol 31, 2013 (suppl; abstr e12537).Georgios LypasK.P.GeorgiouGeorgiaZoulamoglouMenelaosTsoukalasNikolaosZografosGeorgiosPapakostasPavlosBarbounisVasileiosIdentification of breast cancer patients fulfilling NCCN criteria for genetic risk assessment2013(suppl; abstr e12537)10.1200/jco.2013.31.15_suppl.e12537Search in Google Scholar
Armstrong, J., et al., Utilization and Outcomes of BRCA Genetic Testing and Counseling in a National Commercially Insured Population: The ABOUT Study. JAMA Oncol, 2015. 1(9): p. 1251-60.ArmstrongJ.et al.Utilization and Outcomes of BRCA Genetic Testing and Counseling in a National Commercially Insured Population: The ABOUT Study20151912516010.1097/01.ogx.0000482583.01182.eaSearch in Google Scholar
Robson, M.E., et al., American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol, 2010. 28(5): p. 893-901.RobsonM.E.et al.American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility201028589390110.1200/JCO.2009.27.066020065170Search in Google Scholar